Resverlogix Corp. is an advanced-stage biotechnology company that focuses on developing therapies for medical conditions with significant unmet needs. The company's primary asset is apabetalone (RVX-208), a specialized small molecule bromodomain and extra-terminal inhibitor, which is currently undergoing Phase III clinical trials. This investigational treatment aims to address a spectrum of serious ailments, including cardiovascular disease, diabetes mellitus, chronic and end-stage kidney disease, and neurodegenerative disorders. Furthermore, Resverlogix has established a collaboration with Eversana Life Science Services, LLC. This alliance is geared towards supporting the forthcoming commercial introduction of apabetalone as a treatment for COVID-19 in both the United States and Canada. The company's operations are based out of Calgary, Canada.

CEO

Employees

Country

United Kingdom

ISIN

CA76128M1086

Listings

0 Comments

Share your thoughts

FAQ

What is Resverlogix stock price today?▼

The current price of 0VF9.LSE is C$0.12 CAD — it has increased by +0% in the past 24 hours. Watch Resverlogix stock price performance more closely on the chart.

What is Resverlogix stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Resverlogix stocks are traded under the ticker 0VF9.LSE.

What is Resverlogix market cap?▼

Today Resverlogix has the market capitalization of 33M

What is Resverlogix revenue for the last year?▼

Resverlogix revenue for the last year amounts to 0 CAD.

What is Resverlogix net income for the last year?▼

0VF9.LSE net income for the last year is -21.33M CAD.

How many employees does Resverlogix have?▼

As of June 16, 2026, the company has 22 employees.

In which sector is Resverlogix located?▼

Resverlogix operates in the Energy sector.

When did Resverlogix complete a stock split?▼

Resverlogix has not had any recent stock splits.